Early Non-Neuromuscular Symptoms And The Lack of SMN Protein & Zolgensma Versus Spinraza

SMA News Today’s Director of Multichannel Content, Michael Morale, discusses a potential relationship that was found between early non-neuromuscular symptoms and the lack of SMN protein in SMA patients. Also, Community Development Manager Kevin Schaefer reads from a recent post in the SMA News Today forum regarding the recent FDA-approval of Avexis' Zolgensma, and we explain the key differences between this drug and Spinraza.

Are you interested in understanding gene therapy? ExploreGeneTherapy.com has helpful information about gene therapy, including its history and how it is being investigated for the treatment of genetic diseases. Visit www.exploregenetherapy.com

SMA News Today’s Director of Multichannel Content, Michael Morale, discusses a potential relationship that was found between early non-neuromuscular symptoms and the lack of SMN protein in SMA patients. Also, Community Development Manager Kevin Schaefer reads from a recent post in the SMA News Today forum regarding the recent FDA-approval of Avexis' Zolgensma, and we explain the key differences between this drug and Spinraza. Are you interested in understanding gene therapy? ExploreGeneTherapy.com has helpful information about gene therapy, including its history and how it is being investigated for the treatment of genetic diseases. Visit www.exploregenetherapy.com